Inflammation mechanisms and mediators in endocrine diseases
GROUP INFORMATION
The group’s current and future work includes different fields of research into endocrine diseases. First, the role of galectins and other immunoregulatory molecules in patients with autoimmune thyroid diseases (AITD) including Hashimoto’s thyroiditis (HT), Graves’ disease (GD) and Graves’ ophthalmopathy (GO). Over the past few years, we have discovered that patients with AITDs present altered populations of regulatory T cells, increased Th17 cells, decreased levels of dendritic plasmacytoid cells and defective expression of the immune regulatory molecule galectin-9 in antigen-presenting cells. We are planning to study additional regulatory molecules as VIPs in these patients. These abnormalities in immunoregulatory molecules may contribute to the pathogenesis and/or self-perpetuation of AITDs.
We have begun new projects in this field. One such project attempts to characterise the expression of miRNAs (miRNAoma) in thyroid samples from patients with AITDs and healthy controls, and to study the possible use of selected miRNAs as biomarkers in serum samples from AITD patients. We also participated in a collaborative project studying immunoregulatory molecules and miRNAs in different immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis, psoriasis, inflammatory bowel disease and AITDs; trying to find new biomarkers (immunoregulatory molecules) predictive of the severity and response to biological therapies of IMIDs. We are developing new analysis approaches using exosomes as targets containing these relevant biomarkers. The aim of this study is to improve selectivity and efficacy in the use of biological therapies in IMIDs.
Another of the group’s research areas is the process of angiogenesis in gastroentero-pancreatic neuroendocrine tumours and its relationship with somatostatin receptors. We are studying the role of angiopoietins-1 and -2 and their Tie-2 receptor in tumour cells, as well as their association with somatostatin receptors and pathological factors.
In addition, we are studying the role of key molecules in GH-secreting tumours, especially those related to response to treatment with pegvisomant GH antagonist. These studies will include molecular biology techniques, including their characterisation by qRT-PCR, genotyping and sequencing, and studies of association with available clinical information.
Team members
Group leader: Mónica Marazuela Azpíroz Hospital Universitario La Princesa |
Other team members:
|
Marazuela Azpiroz, Mónica. Estudio del microambiente celular en tumores neuroendocrinos gastroenteropancreáticos. Caracterización de la respuesta inmunológica peritumoral y relación con el marcador de hipoxia/estrés tisular lat-1. Grupo Español de Tumores Neuroendocrinos (GETNE). 2017-2019.
Marazuela Azpiroz, Mónica. Estudio de integración de miRNAS y mRNAS en las enfermedades tiroideas autoinmunes: análisis de vías de susceptibilidad y marcadores de la enfermedad. PI16/02091. ISCIII. 2017-2019.
Estudio integrativo de miRNAs y mRNAs secuenciados a partir de biopsias de tiroides de pacientes con ETAI y de controles.
This grant is funded by the 2013-2016 Spanish Science, Technology and Innovation Research Plan and the ISCIII – Subdirectorate General for Evaluation and Promotion of Research – and co-financed by the European Regional Development Fund, Operational Programme Smart Growth 2014-2020 according to Regulation (EU) no. 1303/2013.
Marazuela Azpiroz, Mónica. Identificación y caracterización de microrRNAs implicados en la etiopatogenia de las enfermedades tiroideas autoinmunes. PI13/01414. ISCIII. 2014-2016.
This grant is funded by the State R&D&I Plan and the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación, co-funded by FEDER (the Spanish Federation for Rare Diseases), Operational Programme for the Knowledge-Based Economy (2007-2013), in accordance with Council Regulation (EC) no. 1083/2006 of 11 July 2006 laying down general provisions on the European Regional Development Fund, the European Social Fund and the Cohesion Fund.
Marazuela Azpiroz, Monica.Immunoregulatory molecules and biomarkers predicting response to biological therapies and disease severity in immune-medi-ated inflammatory disorders.BIOIMID PROJECT. ISCIII. PIE13/00041.Coordinador. 2014-2016.
This grant is funded by the State R&D&I Plan and the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación, co-funded by FEDER (the Spanish Federation for Rare Diseases), Operational Programme for the Knowledge-Based Economy (2007-2013), in accordance with Council Regulation (EC) no. 1083/2006 of 11 July 2006 laying down general provisions on the European Regional Development Fund, the European Social Fund and the Cohesion Fund.
Bernabeu I, Alvarez-Escolá C, Quinteiro C, Lucas T, Puig-Domingo M, Luque-Ramírez M, de Miguel-Novoa P, Fernandez-Rodriguez E, Halperin I, Loidi L, Casanueva FF, Marazuela M. The Exon 3-Deleted Growth Hormone Receptor Is Associated with Better Response to Pegvisomant Therapy in Acromegaly. J Clin Endocrinol Metab 2010. 95: 222-229. FI: 6.495(Q1). PMID: 19850678. DOI: 10.1210/jc.2009-1630.
Figueroa-Vega N, Alfonso-Pérez M, Benedicto I, Sánchez-Madrid F, González-Amaro R, Marazuela M. Increased Circulating Pro-Inflammatory Cytokines and Th17 Lymphocytes in Hashimoto’s Thyroiditis. J Clin Endocrinol Metab 2010. 95: 953-962. FI: 6.495(Q1). PMID: 20016049. DOI: 10.1210/jc.2009-1719.
Figueroa-Vega N, Díaz A, Adrados M, Alvarez-Escolá C, Paniagua A, Aragonés J, Martín-Pérez E, Leskela S, Moreno-Otero R, González-Amaro R, Marazuela M. The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors. Endocr.-Relat. Cancer 2010. 17: 897-908. FI: 4.432(Q1). PMID: 20696814. DOI: 10.1677/ERC-10-0020.
Marazuela, M., Paniagua, A. E., Gahete, M. D., Lucas, T., Alvarez-Escola, C., Manzanares, R., Cameselle-Teijeiro, J., Luque-Ramirez, M., Luque, R. M., Fernandez-Rodriguez, E., Castano, J. P., Bernabeu, I. Somatotroph Tumor Progression during Pegvisomant Therapy: A Clinical and Molecular Study. J Clin Endocrinol Metab 2011. 96: 251-259. FI: 5.967(Q1). PMID: 21068147. DOI: 10.1210/jc.2010-1742.
Leskela, Susanna, Rodriguez-Munoz, Ana, de la Fuente, Hortensia, Figueroa-Vega, Nicte, Bonay, Pedro, Martin, Pilar, Serrano, Ana, Sanchez-Madrid, Francisco, Gonzalez-Amaro, Roberto, Marazuela, Monica. Plasmacytoid Dendritic Cells in Patients With Autoimmune Thyroid Disease. J Clin Endocrinol Metab 2013. 98: 2822-2833. FI: 6.310(Q1). PMID: 23666960. DOI: 10.1210/jc.2013-1273.
